Trade names Regumate, Matrix ATCvet code QG03DX90 (WHO) PubChem CID 10041070 Molar mass 310.4299 g/mol | Routes of
administration Oral CAS Number 850-52-2 Formula C21H26O2 Route Oral administration | |
 | ||
Synonyms Allyltrenbolone; RU-2267; 17α-Allylestra-4,9,11-trien-17β-ol-3-one; 17α-Allyl-19-nor-δ-testosterone | ||
Altrenogest
Altrenogest (INN, USAN, BAN) (brand names Regumate, Matrix; former developmental code name RU-2267), also known as allyltrenbolone or allyltrienolone, as well as 17α-allyl-19-nor-δ9,11-testosterone or 17α-allylestra-4,9,11-trien-17β-ol-3-one, is a steroidal progestin of the 19-nortestosterone and allyltestosterone groups related to allylestrenol, norgestrienone, and trenbolone that is widely used in veterinary medicine to suppress or synchronize estrus in horses and pigs. It is available for veterinary use in both Europe (as Regumate) and the United States (as Matrix), and has been marketed as Regumate since the early 1980s.
Contents
In vivo research
According to its manufacturer Roussel Uclaf, altrenogest has weak anabolic and androgenic activity equivalent to 1/20th of that of testosterone. However, no significant androgenic effects have been observed in young stallions or mature mares, and altrenogest has notably been used to maintain pregnancy in mares (similarly to the use of allylestrenol to maintain pregnancy in women) with no incidence of virilization or other abnormalities in filly offspring. On the other hand, minor potential anabolic/androgenic effects have been suggested for altrenogest in pigs.
In vitro research
An in vitro yeast structure-activity relationships bioassay study found that altrenogest was the most potent agonist of both the progesterone receptor (PR) and the androgen receptor (AR) of a large selection of other progestogens as well as androgenic-anabolic steroids (AAS). The observed potency of altrenogest even exceeded that of metribolone (methyltrienolone, R-1881), which was the second most potent compound. In the study, it showed an EC50 of 0.64 nM for the AR and 688% of the relative activational potency of testosterone and an EC50 of 0.3 nM and 1,300% of the relative activational potency of progesterone, with an AR/PR activational potency ratio of 0.53. Although very potent in both activities in vitro, the AR/PR activational potency ratio of altrenogest was in the same range as that of other 19-nortestosterone progestins such as norethisterone, noretynodrel, norgestrel, and allylestrenol (ratio for all < 1.0), whereas the AR/PR activational potency ratio of its 17α-deallylated AAS analogue trenbolone was, at 64, profoundly increased (although the ratio of metribolone (the 17α-methylated variant of altrenogest), at 0.56, was almost the same as that of altrenogest).
Chemistry
Altrenogest is an estrane (C18) steroid and 19-nortestosterone derivative known chemically as 17α-allyl-19-nor-δ9,11-testosterone or 17α-allylestra-4,9,11-trien-17β-ol-3-one. It is one of only two marketed progestins that possesses a 17α-allyl group, the other being allylestrenol. Most other progestins possess a 17α-ethynyl group, while AAS, if they are 17α-substituted, are usually 17α-alkylated (with a methyl or ethyl group). Altrenogest is the 17α-allylated derivative of the AAS trenbolone (and hence can also be referred to as allyltrenbolone or allyltrienolone), which itself is the 9,11-didehydro analogue of the AAS nandrolone (19-nortestosterone).